Found: 5
Select item for more details and to access through your institution.
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 179, n. 3, p. 677, doi. 10.1007/s10549-019-05495-3
- By:
- Publication type:
- Article
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 172, n. 2, p. 413, doi. 10.1007/s10549-018-4906-8
- By:
- Publication type:
- Article
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 6, p. 713, doi. 10.1080/0284186X.2020.1731923
- By:
- Publication type:
- Article
Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry.
- Published in:
- Quality of Life Research, 2020, v. 29, n. 12, p. 3363, doi. 10.1007/s11136-020-02604-4
- By:
- Publication type:
- Article